Oryn Therapeutics

Executive Summary

Oryn Therapeutics is a preclinical-stage biotechnology company pioneering a novel class of macrocyclic peptides, termed Orynotides, derived from naturally occurring theta defensins. Based in Cambridge, MA, the company aims to restore immune balance in diseases characterized by immune system dysregulation. Its platform leverages the high stability and specificity of theta defensins to create therapeutics with potential advantages over conventional biologics. Oryn is initially focusing on indications where immune modulation is critical, though specific pipeline candidates have not been disclosed. The company was founded in 2021 and is privately held, with no public funding or valuation data available. Given its early stage, the company faces typical risks of platform validation and preclinical development.

Upcoming Catalysts (preview)

• H2 2026Lead Program IND-Enabling Studies Initiation60% success
• Q4 2026Preclinical Proof-of-Concept Data Release70% success
• H1 2027Series A Financing Announcement50% success